Pokorney SD, et al.; RENAL AF Investigators. Apixaban for patients with atrial fibrillation on hemodialysis: A multicenter randomized controlled trial. Circulation 2022; 146:1735–1745. doi: 10.1161/CIRCULATIONAHA.121.054990

• PubMed
Pokorney SD, ; RENAL AF Investigators. Apixaban for patients with atrial fibrillation on hemodialysis: A multicenter randomized controlled trial. Circulation 2022; 146:1735–1745. doi: 10.1161/CIRCULATIONAHA.121.054990)| false
• Search Google Scholar
• Export Citation

Lin E, et al. Association between nephrologist ownership of dialysis facilities and clinical outcomes. JAMA Intern Med 2022; 182:1267–1276. doi: 10.1001/jamainternmed.2022.5002

• PubMed
Lin E, Association between nephrologist ownership of dialysis facilities and clinical outcomes. JAMA Intern Med 2022; 182:1267–1276. doi: 10.1001/jamainternmed.2022.5002)| false
• Search Google Scholar
• Export Citation

McCoy EK, Lisenby KM. Aprocitentan (a dual endothelin-receptor antagonist) for treatment-resistant hypertension. J Cardiovasc Pharmacol 2021; 77:699–706. doi: 10.1097/FJC.0000000000001023

• PubMed
McCoy EK, Lisenby KM. Aprocitentan (a dual endothelin-receptor antagonist) for treatment-resistant hypertension. J Cardiovasc Pharmacol 2021; 77:699–706. doi: 10.1097/FJC.0000000000001023)| false
• Search Google Scholar
• Export Citation

Trensz F, et al. Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension. J Pharmacol Exp Ther 2019; 368:462–473. doi: 10.1124/jpet.118.253864

• PubMed
Trensz F, Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension. J Pharmacol Exp Ther 2019; 368:462–473. doi: 10.1124/jpet.118.253864)| false
• Search Google Scholar
• Export Citation

Pivonello R, et al.; LINC 3 Investigators. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): A multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 2020; 8:748–761. doi: 10.1016/S2213-8587(20)30240-0

• PubMed
Pivonello R, ; LINC 3 Investigators. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): A multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 2020; 8:748–761. doi: 10.1016/S2213-8587(20)30240-0)| false
• Search Google Scholar
• Export Citation

Freeman MW, et al.; BrigHTN Investigators. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med [published online ahead of print November 7, 2022]. doi: 10.1056/NEJMoa2213169; http://dx.doi.org/10.1056/NEJMoa2213169

• PubMed
Freeman MW, ; BrigHTN Investigators. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med [published online ahead of print November 7, 2022]. doi: 10.1056/NEJMoa2213169; http://dx.doi.org/10.1056/NEJMoa2213169)| false
• Search Google Scholar
• Export Citation

Reinecke H, et al. A randomized controlled trial comparing apixaban to the vitamin K-antagonist phenprocoumon in patients on chronic hemodialysis: The AXADIA-AFNET 8 study. Circulation [published online ahead of print November 6, 2022]. doi: 10.1161/CIRCULATIONAHA.122.062779; http://dx.doi.org/10.1161/CIRCULATIONAHA.122.062779

• PubMed
Reinecke H, A randomized controlled trial comparing apixaban to the vitamin K-antagonist phenprocoumon in patients on chronic hemodialysis: The AXADIA-AFNET 8 study. Circulation [published online ahead of print November 6, 2022]. doi: 10.1161/CIRCULATIONAHA.122.062779; http://dx.doi.org/10.1161/CIRCULATIONAHA.122.062779)| false
• Search Google Scholar
• Export Citation

Fielding-Singh V, et al. Association between preoperative hemodialysis timing and postoperative mortality in patients with end-stage kidney disease. JAMA 2022; 328:1837–1848. doi: 10.1001/jama.2022.19626

• PubMed
Fielding-Singh V, Association between preoperative hemodialysis timing and postoperative mortality in patients with end-stage kidney disease. JAMA 2022; 328:1837–1848. doi: 10.1001/jama.2022.19626)| false
• Search Google Scholar
• Export Citation

MyTEMP Writing Committee; Garg AX, et al. Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): A pragmatic, cluster-randomised trial. Lancet 2022; 400:1693–1703. doi: 10.1016/S0140-6736(22)01805-0

• PubMed
MyTEMP Writing Committee; Garg AX, Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): A pragmatic, cluster-randomised trial. Lancet 2022; 400:1693–1703. doi: 10.1016/S0140-6736(22)01805-0)| false
• Search Google Scholar
• Export Citation

Bhandari S, et al.; STOP ACEi Trial Investigators. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 2022; 387:2021–2032. doi: 10.1056/NEJMoa2210639

• PubMed
Bhandari S, ; STOP ACEi Trial Investigators. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 2022; 387:2021–2032. doi: 10.1056/NEJMoa2210639)| false
• Search Google Scholar
• Export Citation

Nuffield Department of Population Health Renal Studies Group; Baigent C, et al.; SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium; Anker SD, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400:1788–1801. doi: 10.1016/S0140-6736(22)02074-8

• PubMed
Nuffield Department of Population Health Renal Studies Group; Baigent C, ; SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium; Anker SD, Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400:1788–1801. doi: 10.1016/S0140-6736(22)02074-8)| false
• Search Google Scholar
• Export Citation

EMPA-KIDNEY Collaborative Group; Herrington WG, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med [published online ahead of print November 4, 2022]. doi: 10.1056/NEJMoa2204233; http://dx.doi.org/10.1056/NEJMoa2204233

• PubMed
EMPA-KIDNEY Collaborative Group; Herrington WG, Empagliflozin in patients with chronic kidney disease. N Engl J Med [published online ahead of print November 4, 2022]. doi: 10.1056/NEJMoa2204233; http://dx.doi.org/10.1056/NEJMoa2204233)| false
• Search Google Scholar
• Export Citation

EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 2022; 37:1317–1329. doi: 10.1093/ndt/gfac040

• PubMed
EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 2022; 37:1317–1329. doi: 10.1093/ndt/gfac040)| false
• Search Google Scholar
• Export Citation

Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816

• PubMed
Heerspink HJL, Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816)| false
• Search Google Scholar
• Export Citation